Nov 6, 2018
MediSieve as a finalist of the Hammersmith & Fulham Brilliant Business Awards 2018
Nominated by Upstream, MediSieve made it to the shortlist of this year's Hammersmith and Fulham Brilliant Business Awards.
LONDON – November 06, 2018 – Medical device firm MediSieve is celebrating after making the shortlist of this year's Hammersmith and Fulham Brilliant Business Awards. Nominated in the Best Tech Start-Up category, they were put forward by Upstream, a joint venture between Imperial College and Hammersmith & Fulham Council. All businesses and social enterprises within the West London borough could enter, and winners are set to be named at next month's gala presentation in Hammersmith's Grand Assembly Hall. The ceremony is scheduled for November 7.
Dr George Frodsham, CEO of MediSieve, said: "Clearly we are thrilled to have made the shortlist in these sought-after awards, and the whole team will be attending the ceremony. "We know that the expert judging panel has looked at high-quality entries from more businesses than ever before, which makes being a finalist even more special. Even if we don't win on the night, we're genuinely thrilled to have got this far."
Judges in the Best Tech Start-Up category are looking for outstanding potential, technological innovation and creativity, as well as clear evidence that the technology in question will provide a service people actually need. Something that MediSieve has in abundance. Along with the 13 categories which are judged by an expert panel, there are three public vote categories in the competition, which aims to recognise entrepreneurship and hard work in this part of London.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
